Načítá se...

BMI1 Silencing Enhances Docetaxel Activity and Impairs Antioxidant Response in Prostate Cancer

The BMI1 oncogene promotes prostate cancer progression. High BMI1 expression predicts poor prognosis in prostate cancer (PC) patients. Recent evidence suggests that BMI1 may also play a role in Docetaxel chemoresistance. However, mechanisms and clinical significance of BMI1-related chemoresistance h...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Crea, Francesco, Duhagon Serrat, Maria A., Hurt, Elaine M, Thomas, Suneetha B., Danesi, Romano, Farrar, William L
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3265034/
https://ncbi.nlm.nih.gov/pubmed/20568112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.25522
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!